Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience.
PD-1
advanced urothelial carcinoma
immunotherapy
pembrolizumab
Journal
Therapeutic advances in urology
ISSN: 1756-2872
Titre abrégé: Ther Adv Urol
Pays: England
ID NLM: 101487328
Informations de publication
Date de publication:
Historique:
received:
01
11
2018
accepted:
15
02
2019
entrez:
7
5
2019
pubmed:
7
5
2019
medline:
7
5
2019
Statut:
epublish
Résumé
The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immune checkpoint inhibitors that disrupt the T-cell inhibitory interaction between the programmed cell death (PD)-1 receptor and its ligand (PD-L1). Pembrolizumab, a highly specific, monoclonal antibody directed against PD-1, has demonstrated clinical efficacy as well as a favorable toxicity profile, and has emerged as a new standard of care in the treatment of advanced UC. This review will summarize clinical efficacy from recent trials that led to the approval of pembrolizumab in treating platinum-refractory advanced UC as well as treating patients who are ineligible for first-line cisplatin-containing chemotherapy. While immune checkpoint inhibition has reinvigorated the treatment landscape of advanced UC and generated a great deal of optimism, only a minority of patients benefit. Combination strategies with the goal of increasing response rates are desperately needed as are biomarkers predictive of response.
Identifiants
pubmed: 31057668
doi: 10.1177/1756287219839285
pii: 10.1177_1756287219839285
pmc: PMC6452591
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1756287219839285Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Eur J Cancer. 2006 Jan;42(1):50-4
pubmed: 16330205
J Clin Oncol. 2006 Jul 20;24(21):3451-7
pubmed: 16849761
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
J Clin Oncol. 2009 Sep 20;27(27):4454-61
pubmed: 19687335
J Clin Oncol. 2011 Jun 10;29(17):2432-8
pubmed: 21555688
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Clin Genitourin Cancer. 2014 Apr;12(2):71-3
pubmed: 24355418
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Lancet Oncol. 2017 Feb;18(2):212-220
pubmed: 28081914
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Oncotarget. 2017 May 31;8(35):59901-59914
pubmed: 28938692
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Ther Adv Med Oncol. 2018 Jul 30;10:1758835918788310
pubmed: 30083254
Prog Clin Biol Res. 1988;260:481-5
pubmed: 3283768
J Clin Oncol. 1997 May;15(5):1853-7
pubmed: 9164195